This narrative ethics exploration stems from my happy prostate-specific antigen (PSA) story, though it should not have been, as I annually refuse my family physician's recommendation to purchase PSA screening. The reason for my refusal is I teach ethics to medical students and of course must walk the talk, and PSA screening is not publicly funded in the province of Ontario, Canada. In addition, I might have taken false comfort in 'but all you need is a good index finger' to detect prostate cancer, expounded by a senior physician at a national medical conference in 2010, and applauded by the large audience of physicians. I was compelled to begin this exploration out of survivor guilt, although I will not be a survivor for long, and as a mea culpa to the men similarly situated to me in having late diagnosis of prostate cancer, aggressive tumours and multiple metastases, but who unlike me are dead because they did not experience the physician-educator-based exceptionisms and coincidences that permit me to still be alive. Although my PSA story will always be a happy story, even when my life ends in a few years, the initiation of public funding of PSA screening for all men over 50 would make my PSA story an even happier story.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/medethics-2019-105742 | DOI Listing |
J West Afr Coll Surg
August 2024
Division of Urology, Department of Surgery, College of Health Sciences, University of Abuja, Abuja, Nigeria.
Background: Prostate cancer (PCa) was the most common noncutaneous cancer among Nigerian men in 2020. Despite this high incidence, documented rates may be an underestimation.
Objectives: This study aimed to determine the hospital incidence rate, trends, and characterise the clinicopathologic features, and treatment outcomes of patients with PCa in our institution.
Ethiop J Health Sci
October 2024
Department of Pathology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Background: Tuberculosis (TB) remains the deadliest infectious disease globally, with the kidneys being the most frequently affected organ in the genitourinary system. Isolated prostate involvement by tuberculosis is rare and may mimic prostate cancer. This case report aims to highlight the diagnostic challenges and therapeutic responses associated with isolated prostate tuberculosis, particularly in the context of significantly elevated prostate-specific antigen (PSA) levels in a TB-endemic region.
View Article and Find Full Text PDFProstate Int
December 2024
Department of Internal Urology, College of Medicine, Seoul National University, Seoul, Korea.
Background: To compare the efficacy and toxicity of docetaxel treatment regimens in metastatic castration-resistant prostate cancer (mCRPC).
Methods: We retrospectively analyzed 162 patients diagnosed with mCRPC who underwent docetaxel chemotherapy between 2009 and 2020. The patients were divided into three groups according to the dosage and interval of docetaxel (DCT) chemotherapy regimen: 30 mL/m weekly, 50 mL/m biweekly (every 2 weeks), and 75 mL/m triweekly (every 3 weeks).
Cureus
November 2024
Department of Urology, Mersey and West Lancashire Teaching Hospitals NHS Trust, Liverpool, GBR.
Metastasis of prostate cancer to the testes is exceptionally rare. We report the case of a 67-year-old male with a 10-year history of high-risk prostate cancer, previously treated and currently in remission, who presented with left scrotal swelling. The swelling was clinically and radiologically diagnosed as a hydrocele and treated surgically.
View Article and Find Full Text PDFSemin Arthritis Rheum
December 2024
The IVF Unit, Hadassah Medical Center Mount Scopus, Jerusalem, Israel; Department of Obstetrics and Gynecology, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Objectives: To investigate female fertility in patients with rheumatoid arthritis (RA) exposed to biological drugs.
Methods: In this retrospective cohort study, based on an electronic health record database, 4517 women with RA were compared to 1415 patients with psoriatic arthritis (PsA). Patients were 18-40 years-of-age at diagnosis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!